logo

For the Inventor, By the Inventor

Spring Valley, NY, United States of America

Martin L Sassiver

This inventor holds 10 USPTO granted patents, plus 2 CIPO patents. Top assignee: American Cyanamid Company. Active years: 1982-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martin L Sassiver. Retrieved from https://idiyas.com/inventor/martin-l-sassiver

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10

% Patents Active = 100.0


Average Co-Inventor Count = 2.9

ph-index = 5

Forward Citations = 842(Granted Patents)


Location History:

  • Monsey, NY (US) (1982 - 1984)
  • Spring Valley, NY (US) (1988 - 1998)

Company Filing History:

goldMedal10 out of 3,580 
 
American Cyanamid Company
 patents

Years Active: 1982-1998

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 5770710 - Antitumor and antibacterial substituted disulfide derivatives prepared (1998-06-23),
2. 5770701 - Process for preparing targeted forms of methyltrithio antitumor agents (1998-06-23),
3. 5606040 - Antitumor and antibacterial substituted disulfide derivatives prepared (1997-02-25),
4. 5229411 - Substituted benz[cd]indol-2-(1H)-ones and use as antihypertensive agents (1993-07-20),
5. 5053394 - Targeted forms of methyltrithio antitumor agents (1991-10-01),
6. 4732970 - Antitumor amino acid and peptide derivatives of 1,4-bis(aminoalkyl and (1988-03-22),
7. 4454336 - Derivatives of 3-(formylmethylthio)-propanoate (1984-06-12),
8. 4343938 - 7-[D.alpha.-(Coumarin-3-carboxamido)arylacetamido]-cephalosporanic acids (1982-08-10),
9. 4341703 - 6-[D-.alpha.-(Coumarin-3-carboxamido)arylacetamido]-penicillanic acids (1982-07-27),
10. 4317774 - 6-[D-.alpha.-(Coumarin-3-carboxamido)arylacetamido]-penicillanic acids (1982-03-02),

Title: Innovations of Martin L Sassiver: A Pioneer in Antitumor and Antibacterial Research

Introduction

Martin L Sassiver is an innovative inventor based in Spring Valley, NY, recognized for his significant contributions to the fields of antibacterial and antitumor agents. With a remarkable portfolio of 10 patents, he has devoted his career to developing novel compounds that address critical health challenges.

Latest Patents

Among his latest patents, Martin has detailed a process for producing substituted disulfide derivatives, specifically targeting the LL-E33288 complex, which is known for its antibacterial and antitumor properties. Furthermore, he has introduced a groundbreaking method for constructing targeting agent drug conjugates from methyltrithio antibacterial and antitumor agents, showcasing his expertise in medicinal chemistry.

Career Highlights

Martin L Sassiver has been a pivotal figure at the American Cyanamid Company, where his scientific endeavors have significantly advanced the company’s research in pharmaceuticals. His innovative approaches have not only enhanced the understanding of disulfide compounds but also fostered the development of targeted drug therapies.

Collaborations

Throughout his career, Martin has collaborated with esteemed colleagues, including William J McGahren and George A Ellestad. These partnerships have led to fruitful research outcomes, contributing to both the academic community and the pharmaceutical industry, further underscoring the collaborative spirit necessary for scientific advancement.

Conclusion

Martin L Sassiver’s contributions to the field of medicinal chemistry highlight his passionate commitment to innovation. His patents continue to pave the way for new treatments in the fight against cancer and bacterial infections, underscoring the importance of research and development in healthcare. As a reputable inventor, he stands as a testament to the potential of targeted therapies in modern medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…